Lisa Ricciardi, Cognition CEO (UDG Healthcare)

NIH — and some fa­mil­iar play­ers — back a PhII Alzheimer’s gam­ble in an­oth­er stab at the amy­loid hy­poth­e­sis

Cog­ni­tion Ther­a­peu­tics has a $76 mil­lion grant from the NIH to try out its ap­proach to guard­ing against the synap­tic dam­age be­hind the cas­cade of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.